



WORLD MEDICAL INNOVATION FORUMSM
NEUROSCIENCES | APRIL 27-29, 2015



CONTENTS

- 3 Introductions
- 8 Steering Committee
- 10 The Numbers
- 12 Innovation Advisory Board
- 14 Commercialization Council
- 16 Partners HealthCare: Excellence in the Neurosciences
- 26 Agenda
- 36 About Partners Innovation
- 40 Sponsors
- 46 Information and Events
- 48 Connections
- 50 Acknowledgements
- 55 Maps

Dear Friends:



Welcome to the inaugural World Medical Innovation Forum. Powerful new technologies, with parallel breakthroughs in informatics, genetics and the management of large populations have the potential to profoundly improve health care in the United States and around the globe. Ensuring that patients get the full benefit from those technologies and approaches will require an enhanced

commitment to collaborative innovation and its application in the delivery of care.

We come together over the next three days to further our understanding of new technologies for treating and managing neurologic and psychiatric disease and, through that discussion, assess the overall state of healthcare innovation during a period of transformation. The World Medical Innovation Forum was established to reaffirm the importance of collaborative innovation – academia, industry and government working jointly to push back historic boundaries. Our goal is to provide the insights and tools needed to deliver the best and most effective care to every patient during this time of change. We want attendees to gain actionable insights that they can take back with them to their positions throughout the medical innovation community. Thank you for joining us.

We are grateful to the more than 100 senior executives, investors, clinicians and investigators who interrupted their busy schedules to participate in the Forum, many traveling from a great distance. Hundreds of industry, investment, government, clinical and research leaders are also in attendance. We are pleased that so many of our key faculty from Brigham and Women’s Hospital, Massachusetts General Hospital, McLean Hospital and Spaulding Rehabilitation Network are in attendance. They and their colleagues conduct nearly \$1.5 billion in research annually, which includes funding that drives historic advancements in neurological and psychiatric care.

I would also like to thank the many sponsors representing some of the most innovative companies in healthcare. Without their support, this World Forum would not have been possible. Thank you to the Steering Committee and Planning Team for their outstanding contributions and especially to Anne Klibanski, MD, Chief Academic Officer, and Chris Coburn, Vice President, Innovation, for the vision, resourcefulness and commitment that has resulted in the 2015 World Medical Innovation Forum. We hope that many of you will join us here at the Westin Copley next year, April 25-27, 2016, when we will reconvene the World Medical Innovation Forum and focus on the newest technologies and challenges in the diagnosis, treatment and management of cancer.

David Torchiana, MD
CEO, Partners HealthCare

We Welcome You.

Dear Medical Innovation Leader,

This is an unprecedented era in neuroscience. Never before has the pipeline of novel technologies and therapies been so promising. At the same time, never have the human and economic burdens of neurological disease been so large.

Alzheimer's disease, dementia, depression, epilepsy, multiple sclerosis, Parkinson's disease, and other diseases create an almost incalculable, chronic burden on patients, their families, and society. More than 1 million Americans live with Parkinson's disease; an estimated 400,000 struggle with multiple sclerosis. It is estimated that more than 5 million Americans may suffer from Alzheimer's disease. The burden of depression, schizophrenia and other mental illnesses in the United States is immense to patients and their families and costs society more than \$700 billion a year.

This inaugural World Medical Innovation Forum highlights emerging successes in neurological and psychiatric diseases, and explores their clinical context and impact. Many believe a threshold combining new genomic insights, powerful new therapies, diagnostic tools and electronic systems is finally being crossed. Over the next three days, the clinicians, scientists, executives and investors shaping the future of the field will explore the most promising technology and care in this field.

This Forum is brought to you by Innovation, the arm of Partners HealthCare charged with the commercial application of the breakthroughs of its faculty and staff into patient benefiting technologies, therapeutics, and procedures.

We would like to express our deep appreciation to the many individuals who made this Forum possible. We are particularly grateful to our speakers—including CEOs and top executives of global medical companies, investors, media leaders, and scientific experts—for sharing their substantial expertise and unique perspectives. Generous support provided by our leading sponsors—Biogen, Novartis, Amgen, Boston Scientific, General Electric, MacDougall Biomedical Communications, AstraZeneca, Genzyme, the Massachusetts Life Sciences Center, Polaris, Vertex, HeatlhXL, and Yorn—made this initiative world class.

Finally, we want to recognize the Steering Committee whose insights and standing in the field made the Forum possible. We are especially grateful to the Planning Team whose dedicated work over 18 busy months shaped every aspect of this new undertaking.

Enjoy the Forum!



Christopher Coburn

Vice President,
Innovation,
Partners HealthCare



Anne Klibanski, MD

Chief Academic Officer,
Partners HealthCare





Caring Deeply. Changing Lives.™

As a leader in neurodegenerative disease research and development,
we are proud to sponsor the inaugural World Medical Innovation Forum.

WWW.BIOGEN.COM



STEERING COMMITTEE



Anne Klibanski, MD
Chief Academic Officer, Partners HealthCare,
Laurie Carroll Guthart Professor of Medicine,
Harvard Medical School,
Steering Committee Chair




David Brennan
Former CEO, AstraZeneca



Duke Collier
President, The Braxton Company



Joseph Coyle, MD
Chief Scientific Officer, McLean Hospital,
Eben S. Draper Professor of Psychiatry,
Harvard Medical School (not pictured)



Antonio Chioocca, MD, PhD
Chairman, Neurosurgery, Brigham and Women's
Hospital, Harvey W. Cushing Professor of
Psychiatry, Harvard Medical School



Merit Cudkowicz, MD
Chairman, Neurology, Massachusetts General
Hospital, Julieanne Dorn Professor of Neurology,
Harvard Medical School



Jean-François Formela, MD
Partner, Atlas Ventures



Ricardo Dolmetsch, PhD
Global Head of Neuroscience,
Novartis Institutes for BioMedical Research



Roy Perlis, MD
Director, Center for Experimental Drugs and
Diagnostics, Psychiatry, Massachusetts General
Hospital, Associate Professor of Psychiatry,
Harvard Medical School (not pictured)



Jerrold Rosenbaum, MD
Psychiatrist in Chief, Massachusetts General
Hospital, Stanley Cobb Professor of Psychiatry,
Harvard Medical School



Al Sandrock, MD, PhD
Group Senior Vice President, CMO, Biogen



David Silbersweig, MD
Chairman, Psychiatry, Institute for the
Neurosciences, Brigham and Women's and
Faulkner Hospitals, Stanley Cobb Professor of
Psychiatry, Harvard Medical School



Rudy Tanzi, PhD
MGH Institute for Neurodegenerative Disease,
Director, Genetics and Aging Research Unit,
MGH, Joseph P. and Rose F. Kennedy Professor
of Child Neurology and Mental Retardation,
Harvard Medical School




Ajay Verma, MD, PhD
Vice President of Experimental Medicine, Biogen

Exploring new frontiers in neuroscience.
Dedicated to discovering new medicines.

We have research programs in autism, schizophrenia,
bipolar disorder, Parkinson's disease, alzheimer's and
frontotemporal dementias.

Follow us @Novartis Science or visit www.NIBR.com

The Numbers



1500
MINUTES OF
DISCUSSIONS

600+
NEUROLOGIC DISEASES

VENTURE CAPITALISTS MANAGING
\$7,000,000,000
IN EARLY STAGE INVESTMENTS



*Source: Alzheimer's Association



**STRONG IDEAS NEED STRONG
GLOBAL PARTNERS TO
UNLEASH THEIR POTENTIAL.**

GE Ventures provides small businesses, startups, and entrepreneurs with access to its global network of business units, partners and customers, and to its world-class training resources. All working to identify, scale and accelerate ideas that can advance industries and improve lives.

Learn more at geventures.com.

Imagination at work.

INNOVATION ADVISORY BOARD

The Innovation Advisory Board provides Partners HealthCare with independent guidance on commercial strategy, market potential and collaborative opportunities

Duke Collier

President, The Braxton Company
and IAB Chairman

Joe Cunningham, MD

Managing Director, Santé Ventures

Neil Exter

Partner, Third Rock Ventures

Michael Greeley

General Partner, Foundation Medical Partners

Adele Gulfo

Executive Vice President, Global Collaboration
and Strategic Operations, Mylan

Steve Gullans, PhD

Managing Director, Excel Venture Management

Andy Hurd

CEO, MedeAnalytics

Ed Kania

Managing Partner and Chairman,
Flagship Ventures

Keith Kerman, MD

Operating Partner and Senior Advisor,
The Riverside Company

Paul LaViolette

Managing Partner & COO, SV Life Sciences
and IAB Vice-Chair

Barbara Lubash

Managing Director, Versant Ventures

Amir Nashat, PhD

Managing Partner, Polaris

Steve Oesterle, MD

Senior Vice President for Medicine and
Technology, Medtronic

Ben Pless

CEO, Automatic Technologies

Russ Richmond, MD


CEO, APS

Sue Siegel

CEO, Market Innovations, GE Ventures,
healthymagination & Idea Works

Steve Weinstein

Managing Director, Novartis Venture Fund



COMMERCIALIZATION COUNCIL

The Commercialization Council represents Partners research community
—its innovators, translational investigators and leadership



Paul Anderson, MD, PhD
Associate Chief, Division of Rheumatology, Immunology, and Allergy, BWH; K. Frank Austen Professor of Medicine, Harvard Medical School

Jay Austen, Jr., MD
Chief, Division of Plastic and Reconstructive Surgery, MGH and Harvard Medical School; Associate Professor of Surgery, Harvard Medical School

David Bates, MD
Senior Vice President and Chief Innovation Officer, BWH; Professor of Medicine, Harvard Medical School (not pictured)

Michael Brenner, MD
Chief, Division of Rheumatology, Immunology, Allergy, BWH; Theodore B. Bayles Professor of Medicine, Harvard Medical School

Sree Chaguturu, MD
Vice President, Population Health Management, Partners HealthCare

Jessica Dudley, MD
Chief Medical Officer, Vice President, Care Redesign, Brigham and Women's HealthCare

Omid Farokhzad, MD
Physician-scientist, Department of Anesthesiology, BWH; Faculty Member, Brigham Research Institute Cancer Research Center, BWH; Associate Professor, Harvard Medical School

Maurizio Fava, MD
Director, Clinical Research Program, MGH; Executive Vice Chair, Department of Psychiatry, MGH; Slater Family Professor of Psychiatry, Harvard Medical School

Mason Freeman, MD
Chief, Lipid Metabolism Unit, MGH; Director, Translational Medicine Program, Center for Computational and Integrative Biology, Clinical Research Program, MGH; Professor of Medicine, Harvard Medical School

Ole Isacson, MD
Founding Director, Neuroregeneration Research Institute, McLean Hospital/Harvard Medical School; Professor of Neurology and Neuroscience, Harvard Medical School

Christiana Iyasere, MD
Associate Director, Innovation Support Center (ISC) and Inpatient Clinician Educator Service, MGH

Jeff Karp, PhD
Associate Professor, BWH and Harvard Medical School

Ramin Khorasani, MD
Vice Chair, Department of Radiology; Director, Center for Evidence-Based Imaging, BWH

Alexa Boer Kimball, MD
Senior Vice President, Practice Improvement, MGPO; Vice Chair, Department of Dermatology, MGH; Associate Professor, Harvard Medical School

Adam Landman, MD
Emergency Physician and Chief Medical Information Officer for Health Information Innovation and Integration, BWH



Calum MacRae, MD, PhD
Chief, Cardiovascular Medicine, BWH; Associate Professor, Harvard Medical School (not pictured)

Orhun Muratoglu, PhD
Alan Gerry Scholar, MGH; Co-Director, Harris Orthopaedics Lab, MGH; Director, Technology Implementation and Research Center, MGH; Associate Professor, Harvard Medical School

Anders Naar, PhD
Professor of Cell Biology, MGH Cancer Center and Harvard Medical School

Harry Orf, PhD
Senior Vice President, Research, MGH

Dennis Orgill, MD, PhD
Vice Chair, Quality Improvement, Department of Surgery, BWH; Director, BWH Wound Care Center; Professor of Surgery, Harvard Medical School

Mark Poznansky, MD, PhD
Attending Physician in Infectious Diseases Medicine, MGH; Director, Vaccine and Immunotherapy Center, MGH; Associate Professor of Medicine, Harvard Medical School

Brian Seed, MD, PhD
Founding Director, Center for Computational and Integrative Biology, MGH; Professor of Genetics, Harvard Medical School

Christine Seidman, MD
Professor of Genetics, BWH; Director, Cardiovascular Genetics Center, Harvard Medical School and BWH; Thomas W. Smith Professor of Medicine, Harvard Medical School; Investigator, Howard Hughes Medical Institute

Susan Slaughaupt, PhD
Scientific Director, MGH Research Institute; Professor of Neurology, Massachusetts General Hospital and Harvard Medical School

Rudy Tanzi, PhD
MGH Institute for Neurodegenerative Disease, Director, Genetics and Aging Research Unit, MGH, Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation, Harvard Medical School

Guillermo Tearney MD, PhD
Mike and Sue Hazard Family Research Scholar, MGH; Professor of Pathology, Harvard Medical School

Ravi Thadani, MD
Chief, Division of Nephrology, MGH; Associate Director of Research, Partners HealthCare; Professor of Medicine, Harvard Medical School

Christopher Thompson, MD
Director, Therapeutic Endoscopy, BWH; Director, Developmental Endoscopy laboratory, BWH ; Assistant Professor of Medicine, Harvard Medical School

Mehmet Toner, PhD
Associate Director, Center for Engineering in Medicine, MGH and Shriners Hospital for Children; Professor of Surgery, Harvard Medical School

Howard Weiner, MD
Founder and Director, Partners HealthCare Multiple Sclerosis Center; Robert L. Kroc Professor of Neurology, Harvard Medical School



PARTNERS HEALTHCARE:

Excellence in the Neurosciences

Breakthrough research throughout Partners HealthCare – including the Massachusetts General Hospital, Brigham and Women’s Hospital, McLean Hospital and Spaulding Rehabilitation Network – is redefining how healthcare is delivered. From neuroinformatic analysis of big data to cutting-edge gene-editing technology, the research in progress at Partners HealthCare is truly game changing.

Partners HealthCare innovators are finding ways to prevent, halt, and defeat neurological diseases ranging from Alzheimer’s to multiple sclerosis. A few highlights of the work underway at the hospitals show the bright promise of the field.

Alzheimer’s disease

Alzheimer’s disease remains the only top 10 cause of death in the U.S. that cannot be prevented, stalled or cured. Research underway at Partners aims to change that for the estimated 5.3 million Americans who suffer from this relentless disease.

A novel technique unveiled last year by Rudy Tanzi, PhD, the Joseph P. and Rose F. Kennedy Professor of Child Neurology at MGH, promises to open the doorway for more vigorous drug discovery. Tanzi made worldwide headlines with reports of an ‘Alzheimer’s-in-a-dish’ approach that replaces mouse models with a 3-D culture system. His group also evaluates the genetic underpinnings of the disease via the Alzheimer’s Genome Project, which has identified several gene candidates to date.

At the BWH Center for Alzheimer Research and Treatment (CART), researchers refine new strategies for early diagnosis, including highly sensitive cognitive tests, biomarkers and neuroimaging techniques. Clinical trials of five promising therapeutics are currently in progress, alongside long-term observational studies to identify early symptoms of the disease.

Neuroimaging studies underway at McLean Hospital have uncovered important changes in the brain’s white matter that appear to underlie Alzheimer’s symptoms such as anxiety, disinhibition, sleep disturbances, and abnormal movement.

Finally, innovations in big data allow researchers to mine electronic health records for clues about the onset and progression of Alzheimer’s disease. The NeuroDiscovery Center oversees a state-of-the-art repository of clinical information, part of the Partners HealthCare BioBANK, collected from thousands of neurology patients to test biomarker hypotheses and accelerate drug discovery for Alzheimer’s disease, Parkinson’s disease, and other neurological disorders.



Autism

The recent rise in autism spectrum diagnoses has triggered intense research into the disorder's mysterious causes. Identical twin studies suggest a strong genetic basis, but the exact mechanisms remain unclear.

Partners HealthCare researchers are making headway into understanding the biological basis of autism and enhancing the daily lives of these children and their caregivers.

In 2010, scientists at McLean Hospital introduced the world's first biologically based test for autism. The test identifies aberrant brain circuitry via MRI, and is 94% accurate at detecting individuals with high-functioning autism.

Earlier this year, Christopher Cowan, PhD, a McLean Hospital psychiatrist, reported that a gene previously linked to autism is responsible for connecting key brain regions involved in sensory processing. The findings may explain why individuals with autism have difficulty processing stimuli from touch, sound and vision.

At the MGH, the TRANSCEND imaging and body biomarker programs, directed by MGH researcher Martha Herbert, MD, PhD, aim to uncover the mechanisms of autism and other neurodevelopmental disorders. Short for Treatment Research and NeuroSCience Evaluation of Neurodevelopmental Disorders, TRANSCEND uses a number of tools, including MRI, EEG, and MEG to assess brain activity in children as they complete various tasks. A biomarker study searches for metabolic and immune markers in urine and blood samples, hoping to shed light on the brain-body connection in people with autism.

Landmark discoveries on the genetic basis of autism and schizophrenia stem from ongoing work at the MGH Center for Human Genetic Research and the international Psychiatric Genomics Consortium. Leaders Mark Daly, PhD, James Gusella, PhD, and their collaborators have uncovered seven genes and a number of genetic changes implicated in the diseases. Daly's leadership role in the largest autism exome sequencing study to date has fueled discovery in this field.

Many of these studies are performed collaboratively with the Athinoula A. Martinos Center for Biomedical Imaging, founded in partnership with the MGH, Harvard and MIT. The Martinos Center uses a collaborative and multidisciplinary model to advance the entire spectrum of innovation – from the basic biosciences through to clinical investigation, development and application. Groundbreaking discoveries in the fields of brain mapping and tractography continue to emerge, benefiting patients with autism as well as neurodegenerative disorders such as Alzheimer's disease.

Depression

Major depression is among the most common and most debilitating of psychiatric disorders, affecting more than 350 million people globally. One million deaths are attributed to depression each year, according to the World Health Organization.

Effective treatments for depression exist, but predicting a patient's response to any given treatment is challenging. The McLean Laboratory for Translational and Affective Neuroscience aims to discover predictive factors that could usher in a new era of personalized medicine for people with depression. The lab relies on a variety of neuroimaging techniques, including EEG, fMRI, and PET to explore the specific patterns of brain activity that correlate with treatment response, depression severity, anxiety and other symptoms of depression.

Novel neurostimulation treatments for psychiatric disorders such as depression and bipolar disorder are under development by McLean spinoff Tal Medical, a clinical stage medical device company. Early human trials of the company's first-in-class and noninvasive technique, low-field magnetic stimulation (LFMS), have shown promise in treating major depressive disorder and bipolar depression.

In collaboration with Partners HealthCare researcher Maurizio Fava, MD, Vice Chairman of Psychiatry at MGH, biotech firm Neuralstem is in pursuit of stem cell therapies for major depressive disorder and other psychiatric disorders. Fava is currently overseeing a Phase II trial of Neuralstem's small molecule NSI-189. The company is also pursuing Phase III trials for a spinal cord stem cell treatment known as NSI-566 as a potential therapy for amyotrophic lateral sclerosis (ALS), ischemic stroke, spinal cord injury, and multiple sclerosis.

Finally, the BWH Department of Psychiatry is taking a multi-modal biomarker approach to the stratification of patient disease subtypes. These studies promise to advance current efforts to guide diagnostic classification and design targeted therapeutics.

Epilepsy

Epilepsy is the fourth-most common neurological illness, following migraine, stroke and Alzheimer’s disease. An estimated 1 in 26 Americans will be diagnosed with epilepsy at some point in their lives. The disease can have a devastating effect on quality of life. Specialized facilities and expertise at Partners HealthCare hospitals are raising the bar for epilepsy diagnosis and treatment.

At the intersection of psychiatry, neurology and anesthesia is Emad Eskandar, MD, a neurosurgeon at the MGH and the Charles Anthony Professor of Neurosciences at Harvard Medical School. A renowned expert in the use of deep brain stimulation for Parkinson’s disease and dystonia, Eskandar’s group is also advancing novel surgical treatments for epilepsy, traumatic brain injury and stroke. Eskandar’s basic science research in primates and humans has revealed the multifaceted role of the basal ganglia, a region of the brain tied to learning, motivation, depression and drug addiction.

As Director of Stereotactic and Functional Neurosurgery at MGH, Eskandar plays a leadership role in the MGH Epilepsy Service – one of the only U.S. epilepsy centers equipped to examine brain electrical activity and structure in minute detail via high-resolution (7 tesla) MRI and magnetoencephalography (MEG). Multidisciplinary collaboration among epileptologists, neurosurgeons, neuroradiologists, neuropsychiatrists and anesthesiologists raises the bar for surgical outcomes. A neurostimulation device known as the NeuroPace® System recently gained FDA approval following successful clinical trials at the MGH. The smart device detects the aberrant electrical activity that precedes partial onset seizures and targets low levels of electrical stimulation to the area of seizure focus.

Also a leader in the MGH Epilepsy Service, Sydney Cash, MD, Associate Professor of Neurology and the Elizabeth Riley and Dan Smith MGH Research Scholar, has pioneered the use of microelectrode arrays in understanding and eventually controlling seizures. His group employs multiple systems which are able to record the activity of single neurons in the brains of patients with epilepsy. With this approach, they are redefining what a seizure is, how they spread and how they might be predicted. The same technology is being used to explore the neural mechanisms which underlie language, sleep and other fundamental brain functions.



Multiple sclerosis

Multiple sclerosis afflicts an estimated 2.3 million people around the world. Despite extensive research in this field, the underlying causes remain unclear. Partners HealthCare’s researchers are devising ways to halt the progression of disease, reverse disability and loss of function, and prevent new cases of MS.

Through the “Decade of Discovery,” the Partners Multiple Sclerosis Center at Brigham and Women’s Hospital, led by Howard Weiner, MD, has unveiled powerful therapeutics for MS and made strides toward unraveling immunologic origins of the disease. Both BWH and MGH are sites for a multi-center clinical trial evaluating a neuroprotective therapy for progressive MS, a subtype of MS with no current proven therapies, with MGH serving as the clinical coordinating center for the study.

A number of research projects are ongoing, including MRI-based efforts to visualize the disease process and inflammatory changes in the brain. At the Martinos Center for Biomedical Imaging at MGH, Eric Klawiter, MD and Caterina Mainero, MD utilize an ultra-high gradient Human Connectome MRI and the center’s 7T MRI to evaluate how brain connectivity changes and cortical pathology relate to cognitive dysfunction and other manifestations of disability in MS. The Natural History Study at BWH integrates research projects in proteomics, gene expression, genetics, and immune phenotypes to define novel biomarkers of disease. The Genes and Environment in Multiple Sclerosis (GEMS) Research Study, headed by neurologist Philip De Jager, MD, will follow 5,000 participants with known risk factors for MS to uncover the hidden interplay between genetics, environmental, and immune factors that raise a person’s risk of developing MS.

Advanced informatics allow researchers to integrate genetic, immunological, and clinical data from a large cohort of MS patients into a predictive model capable of forecasting individual patients’ responses to therapy. De Jager collaborates with the Informatics to the Bedside (i2b2) initiative to mine electronic health records for vast amounts of information that might otherwise go unused. Codified and narrative data from doctors’ notes are used to enrich studies of MS progression and treatment.

Parkinson’s disease

Parkinson’s disease remains one of the most common neurodegenerative diseases of the elderly, affecting an estimated 500,000 to 1 million people in the United States alone.

Like other neurodegenerative disorders, including Alzheimer’s, Huntington’s, and amyotrophic lateral sclerosis (ALS), Parkinson’s disease has no effective therapies. The human and economic impacts of a Parkinson’s diagnosis are immense – approximately \$10.8 billion dollars are expended every year in the U.S. on medical care and indirect costs of living with the disease.

Thanks to advances made by Partners HealthCare researchers, Parkinson’s patients of the not-so-distant future may benefit from personalized medicine. A major player in the field of Parkinson’s research is the Neurogenomics Lab, led by Clemens Scherzer, MD, an associate neurologist at the BWH and MGH, associate professor of neurology at HMS, and Co-Director of the Harvard NeuroDiscovery Biomarker Program. The Lab’s genomicists, computational biologists and clinical scientists use next-generation genomics technologies to explore how the brain differs in patients with Parkinson’s, Huntington’s or Alzheimer’s disease. Identifying novel biomarkers and increasing the efficiency of drug discovery are top goals.

At McLean Hospital, researchers are using gene correction to reverse specific mutations underlying the mitochondrial DNA damage inherent in Parkinson’s disease. In addition, the hospital’s Neuroregeneration Institute, led by Ole Isacson, MD, aims to accelerate the treatment of Parkinson’s and other degenerative brain disorders. Isacson’s research has uncovered specific characteristics of the brain cells most vulnerable to degeneration. The findings may benefit patients with Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS).





Schizophrenia

It is clear that genetics plays a vitally important role in the etiology and pathogenesis of schizophrenia: 10% of people with an affected first-degree relative will develop the illness, while only 1% of the general population will be diagnosed with schizophrenia. The specific genetic mechanisms at play, however, are not well defined.

Collaborations among investigators at the MGH, McLean, and Harvard are driving forward the Brain Genomics Superstruct project, overseen by Randy Buckner, PhD, Director for the MGH Psychiatric Neuroimaging Research Program. Brain imaging and genetic information from patients with schizophrenia and other neuropsychiatric disorders are entered into a database that will help propel therapeutic discovery via detailed comparisons of schizophrenia with other illnesses.

The Martinos Center is home to the MGH Schizophrenia Program, where investigators benefit from one-of-a-kind neuroimaging technologies like specialized fMRI. Current efforts aim to untangle the neurobiological mechanisms at work in patients with schizophrenia. Combined with genetic tests, these imaging studies are potent tools for identifying genes that raise the risk of schizophrenia, and for revealing the impacts of these genes on brain structure and function.

The BWH Functional Neuroimaging Laboratory (FNL) uses a symptom-oriented approach to explore deep-brain structural abnormalities that underlie psychiatric illnesses such as schizophrenia. Novel fMRI methods and innovative imaging modalities developed at the FNL continue to uncover important neural circuitry abnormalities responsible for schizophrenic hallucinations and delusions. Collaborations with researchers at other academic centers aim to fine-tune a novel cognitive behavioral treatment approach for patients with paranoia, and predict how patients will respond to various treatments.

Investigators at the McLean Laboratory for Psychiatric and Molecular Neuroscience are exploring the genetic and structural overlaps between schizophrenia, bipolar disorder, and autism. A recent post-mortem study revealed for the first time that bipolar disorder is accompanied by changes in brain morphology similar to those found in patients with schizophrenia. Researchers are currently studying genetic aberrations in Huntington’s disease, Alzheimer’s disease, and substance abuse.

Through the Schizophrenia and Bipolar Research Program, McLean investigators are performing fMRI studies of auditory hallucinations and large-scale brain network abnormalities in patients with schizophrenia and bipolar disorder.

Sleep disorders

Sleep disorders are exceptionally common. Of the estimated 70 million Americans affected by disorders of sleep and wakefulness, nearly 18 million have sleep apnea – many of them undiagnosed.

To address this problem, numerous clinical trials and basic science studies are underway at Partners HealthCare. John Winkelman, MD, PhD, Chief of the MGH Sleep Disorders Clinical Research Program, studies the effects of pharmacological and cognitive behavioral therapies on patients with sleep disorders and comorbid psychiatric illness such as major depressive disorder or sleep-related eating disorder.

The MGH Division of Sleep Medicine, is one of the few such divisions in the nation to be housed within a hospital neurology department. Patients treated at the sleep laboratory benefit from the combined multidisciplinary expertise of neurology, psychiatry, pulmonary and pediatric specialists. Sophisticated technology in use at the sleep laboratory – one of the only hotel-like facilities in the U.S. – offers patients the unique opportunity to benefit from high-resolution snapshots of brain activity during sleep studies.

At BWH, a newly formed Division of Sleep and Circadian Disorders spans the departments of medicine and neurology, and encompasses the similarly new Sleep Disorders Service. The service offers home sleep testing and specialty care for patients with neurologic complications such as movement disorders, behavioral disturbances, epilepsy and stroke.

The BWH Program in Sleep and Cardiovascular Medicine and Sleep Medicine Epidemiology (PSCM-SME) aims to improve patient care through a number of local and national epidemiological studies. A particular emphasis is placed on individuals with combined sleep and cardiovascular disease.

Scientists at McLean’s sleep research lab are investigating the neurocognitive and behavioral effects of sleep deprivation, as well as the influences of drug abuse.

Stroke

As a leading cause of long-term disability, the costs associated with stroke are enormous: \$34 billion per year in the U.S. alone.

Partners’ Telestroke Program, led by the MGH, is making strides to enhance the diagnosis and treatment of stroke, in hopes of decreasing these immense human and economic burdens. The Telestroke Program allows an extensive network of hospitals to benefit from the world-class expertise of Partners’ stroke specialists.

In addition, the Neurology of Vision Lab – overseen by MGH professors Lucia Vaina, MD, PhD, and Ferdinando Buonanno, MD – links stroke neurology to neuroscience and multimodal brain imaging to address problems with visual perception and cognition.

At the MGH Clinical Proteomics Research Center, researchers are discovering prognostic tools and novel biomarkers to enhance clinical diagnosis and treatment in patients with acute neurovascular injury. The Center’s director, MingMing Ning, MD, oversees a NIH-funded clinical study, “Clinical Proteomics Research (CPR) on the Brain” that seeks to identify changes in the proteomic profiles of patients with ischemic brain injuries, chronic neurologic diseases, or systemic vascular diseases, relative to their healthy counterparts. The results will provide insight into the biological pathways underlying various therapeutic interventions.

Additional research at the Center focuses on the development of a proteomic repository and database using plasma, cerebrospinal fluid, and urine collected from patients.

These projects, and many more in progress at Partners HealthCare, are steering CNS healthcare into a new era – one marked by opportunity, innovation and success. ●

Science, no matter how **advanced**, is only as meaningful as the lives it **transforms**.

At Boston Scientific, we believe that only an innovation realized can improve health, change an outlook or transform a life. That's why we're committed to pioneering, innovating and advancing science. Our heritage of discovery continues to drive our passion for meaningful innovations that address unmet clinical needs across a wide range of medical conditions and help patients live healthier, longer lives.

Visit www.bostonscientific.com to learn more.

scientists, artists, leaders, thinkers, doers



Our passion for communicating scientific and medical breakthroughs energizes us to come to work every day. Our belief in the importance of our clients' missions drives an unmatched level of customer service.

Visit www.macbiocom.com to learn more.

MACDOUGALL
biomedical communications

be seen, be heard, be understood.

Agenda

MONDAY, 27TH

11:30 AM

Discovery Cafe: Sharing Perspectives
NOVARTIS BALLROOM

Top neuroscience faculty from Brigham and Women’s Hospital, Massachusetts General Hospital and McLean Hospital – all appointed at Harvard Medical School – gather in an intimate setting to explore their specific areas of expertise. Attendees select the faculty member they would like to share lunch with.

2:00 PM

Welcome
BIOGEN BALLROOM

David Torchiana, MD, CEO, Partners HealthCare

INTRODUCTION BY

Anne Klibanski, MD, Chief Academic Officer, Partners HealthCare;
Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

2:10 PM

Neurocare, Neuromarkets, and Neuro Challenges
BIOGEN BALLROOM

Session
101

Fifty million people worldwide suffer from neurodegenerative diseases costing more than \$650 billion annually. Fueled by DNA editing technologies, genetic sequencing, new drugs and other breakthroughs, the neuromarket has taken flight. Three senior clinical leaders briefly describe the context for these innovations including unmet needs, neurocare trends, and the ongoing challenges of developing new technologies for the CNS.

MODERATOR

Jonathan LaPook, MD, Chief Medical Correspondent, CBS News

Antonio Chiocca, MD, PhD, Chairman, Neurosurgery, Brigham and Women’s Hospital; Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School

Merit Cudkowicz, MD, Chairman, Neurology, Massachusetts General Hospital;
Julieanne Dorn Professor of Neurology, Harvard Medical School

Scott Rauch, MD, President and Psychiatrist in Chief, McLean Hospital;
Rose-Marie and Eijk van Otterloo Chair of Psychiatry, Harvard Medical School

2:50 PM

Over the Horizon: Witnessing the Disruption of Neurocare
BIOGEN BALLROOM

Session
102

This panel of unmatched neuro-futurists describe technologies and therapies that promise to disrupt neurocare in the future. From implantable neuroprosthetics and real time brain monitoring to effective, safe precision-targeted medications, game-changing technologies in the pipeline or under development.

MODERATOR

Alice Park, Writer, TIME Magazine

Ajay Verma, MD, PhD, Vice President of Experimental Medicine, Biogen

Geoffrey Ling, MD, PhD, Director, Biological Technologies Office, DARPA

Moncef Slaoui, PhD, Chairman of Global R&D and Vaccines, GlaxoSmithKline

3:40 PM

Session
103

Transformation and Innovation: Conflict? Collision? Opportunity?
BIOGEN BALLROOM

The health care landscape is evolving at a breakneck pace. Chief executives from the provider, pharmaceutical and medical device communities will share perspectives on how transformative innovation can elevate patient care and population health in a period when financial sustainability and affordability might appear to be competing priorities.

MODERATOR

Nancy Snyderman, MD, Chief Medical Editor, NBC News (ret.)

Jeff Leiden, MD, PhD, CEO, Vertex Pharmaceuticals

Mike Mahoney, CEO, Boston Scientific

Betsy Nabel, MD, President, Brigham and Women’s Hospital;
Professor of Medicine, Harvard Medical School

George Scangos, PhD, CEO, Biogen

Peter Slavin, MD, President, Massachusetts General Hospital;
Professor of Healthcare Policy, Harvard Medical School

4:30 PM

Session
104

Gene to Drug: Kansas to Oz, Making it Happen in the Real World
BIOGEN BALLROOM

Modern drug discovery often starts with human genetics to validate a target or mechanism and then pursues a specific gene in the drug discovery and development process. This model has had great impact in certain oncology drug programs, but can this approach work for neurological drug development? The panel of industry heavyweights discusses what is possible, realistic and likely, as the field further unfolds.

MODERATOR

Jonathan LaPook, MD, Chief Medical Correspondent, CBS News

David Altshuler, MD, PhD, Executive Vice President of Global Research and CSO, Vertex Pharmaceuticals

Mark Fishman, MD, President, Novartis Institutes for BioMedical Research

Jeffrey Gulcher, MD, PhD, Co-Founder and CSO WuXi NextCODE

Sean Harper, MD, Executive Vice President, Research and Development, Amgen

5:30 PM

Welcome Reception
GE BALLROOM

6:45 PM

Dinner Program
NOVARTIS BALLROOM

The chairman and CEO of one of the world’s largest technology companies will share thoughts on the next generation of neuroscience innovation and the challenges and opportunities that will affect growth in the medtech sector.

INTRODUCTION BY

Edward Lawrence, Chairman, Board of Directors, Partners HealthCare

MODERATOR

Nancy Snyderman, MD, Chief Medical Editor, NBC News (ret.)

Jeff Immelt, CEO, General Electric

Please find all speaker bios on our website at: worldmedicalinnovation.org

AGENDA | TUESDAY



NOVARTIS BALLROOM



12:00 PM

Lunch Program - CEO One-On-One

NOVARTIS BALLROOM

Session
206

Last month, Biogen made worldwide news when it reported that its experimental drug for Alzheimer’s disease showed promise in slowing cognitive decline. Biogen CEO George Scangos, PhD will discuss this breakthrough and industry efforts to move from slowing the damage from neuro disease to stopping disease progression.

INTRODUCTION BY

Peter Slavin, MD, President, Massachusetts General Hospital;
Professor of Healthcare Policy, Harvard Medical School

MODERATOR

Kyra Phillips, Anchor and Correspondent, CNN

George Scangos, PhD, CEO, Biogen

12:45 PM

Secretary One-On-One

Session
207

Since her confirmation by the Senate last year, HHS Secretary Sylvia Mathews Burwell has established herself as a champion of medical innovation. She will share her thoughts on how the federal government can work with industry to advance precision medicine and the development of new treatments and cures.

INTRODUCTION BY

David Torchiana, MD, CEO, Partners HealthCare

Hon. Sylvia Matthews Burwell, Secretary,
US Department of Health & Human Services

1:25 PM

Neurostimulation: First Line Therapy?

BIOGEN BALLROOM

Session
208

Electroceuticals, new therapies based on the body’s bioelectric signals, rather than its chemistry, are using the electrical language of the body to target individual nerve fibers to treat an array of conditions by modulating the neural impulses.

MODERATOR

Peter Ford, Founder and CEO, Control Bionics

Emad Eskandar, MD, Neurosurgeon, Massachusetts General Hospital;
Charles Pappas Professor of Neurosurgery, Harvard Medical School

Frank Fischer, CEO, NeuroPace

Lothar Krinke, PhD, Vice President and General Manager,
Brain Modulation, Medtronic

Ben Pless, CEO, ATI

Mark Demitrack, MD, Chief Medical Officer, Neuronetics

2:15 PM

Olympus Explained: Neuroinvesting for Mortals

BIOGEN BALLROOM

Session
209

Five neuro industry investment leaders discuss the special opportunities and challenges of investing in CNS technologies and challenges.

MODERATOR

Meg Tirrell, Biotech & Pharma Reporter, CNBC

Doug Cole, MD, General Partner, Flagship Ventures

Jean-François Formela, MD, Partner, Atlas Ventures

Corey Goodman, PhD, Managing Partner, venBio

Rajiv Kaul, Select Biotechnology Portfolio and Advisor Biotechnology Fund,
Fidelity Investments

Sue Siegel, CEO, GE Ventures & healthymagination

3:15 PM

FOCUS SESSIONS I

National Security Through Neurodevelopment:
Country Initiatives to Meet CNS Challenges

BOSTON SCIENTIFIC BALLROOM

Session
210

International panel members will review global initiatives to drive understanding of the CNS to develop new tools, diagnostics and therapeutics as well grow new industries.

MODERATOR

John Roberts, Senior National Correspondent, Fox News

Miri Polachek, Executive Director, Israel Brain Technologies

Michael Hodin, PhD, Executive Director, Global Coalition on Aging;
Managing Partner, High Lantern Group

Tom Large, PhD, Senior Vice President, Preclinical Research
and Translational Medicine, Sunovion Pharmaceuticals

Luc Truyen, MD, PhD, Vice President, Neuroscience External Affairs, Chair,
Johnson & Johnson Global Fight Against Alzheimer's Disease

Technology, Pathology, Radiology:
Changing the Game through Neurodiagnostics

BIOGEN BALLROOM

Session
211

While both pathology and radiology have traditionally been used to guide neurological interventions, four experts explain why advanced diagnostics technologies are shifting our fundamental understanding of neurological disease. This understanding (and technology) is serving as the basis for a systems approach to diagnosing, intervening, and managing neurodegenerative disease.

MODERATOR

Jerrold Rosenbaum, MD, Psychiatrist-In-Chief;
Stanley Cobb Professor of Psychiatry, Harvard Medical School

Jeffrey Golden, MD, Chairman, Department of Pathology,
Brigham and Women’s Hospital; Ramzi S. Cotran Professor of Pathology,
Harvard Medical School

Jeff Hersh, MD, PhD, Chief Medical Officer, GE Healthcare

David Louis, MD, Pathologist-in-Chief, Massachusetts General Hospital;
Benjamin Castleman Professor of Pathology, Harvard Medical School

Bruce Rosen, MD, PhD, Director, Athinoula A. Martinos Center for
Biomedical Imaging, Massachusetts General Hospital; Professor of Radiology,
Harvard Medical School

Autism and Neurodevelopment: Are Therapies Possible Today?

GE BALLROOM

Session
212

Autism spectrum disorder (ASD), the high-cost, lifelong, neurological condition that currently affects up to 1 child in every 88 and about 1 percent of adults, has no cure, nor is there global consensus on which intervention is most effective. While many drugs are prescribed for the associated symptoms, there are no approved drugs specifically to treat core symptoms. National experts and high profile patient advocates discuss current and future therapeutic approaches.

MODERATOR

Ron Suskind, Pulitzer Prize-winning Journalist and Author,
Director of the Project on Public Narrative, Harvard University

Randall Carpenter, MD, Translational Medicine Consultant; Research Affiliate,
Department of Brain and Cognitive Sciences, MIT

Mark Daly, PhD, Chief, Analytic and Translational Genetics, Massachusetts General
Hospital; Associate Professor of Medicine, Harvard Medical School

Christopher McDougle, MD, Director, Lurie Center for Autism,
Massachusetts General Hospital for Children; Nancy Lurie Marks Professor of Autism,
Harvard Medical School

Ricardo Dolmetsch, PhD, Global Head of Neuroscience,
Novartis Institutes for Biomedical Research

Bob Wright, Co-Founder, Autism Speaks; Senior Advisor, Lee Equity Partners





	Session 213	<p>Psychiatric Targets: Finally New Mechanisms?</p> <p>NOVARTIS BALLROOM</p> <p>Major psychiatric disorders such as schizophrenia, major depressive and bipolar disorders are severe, chronic and debilitating, and are associated with high disease burden and healthcare costs. Early diagnosis is difficult, misdiagnosis is frequent, and there are no objective tests that aid in the prediction of individual responses to treatment. Despite these challenges, the medical approach to mental illness is changing dramatically. Panel members review ongoing clinical, molecular, genetic, neuroimaging and neurophysiological findings.</p> <p>MODERATOR</p> <p>Gideon Gil, Health and Science Editor, The Boston Globe</p> <p>Deborah Dunsire, MD, CEO, FORUM Pharmaceuticals</p> <p>Mike Ehlers, MD, PhD, Neuroscience Chief Science Officer, Pfizer</p> <p>Maurizio Fava, MD, Executive Vice Chair, Massachusetts General Hospital Psychiatry; Slater Family Professor of Psychiatry, Harvard Medical School</p> <p>Corey McCann, MD, PhD, Founder and CEO, Pear Therapeutics</p> <p>David Silbersweig, MD, Chairman, Psychiatry, Brigham and Women's Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School</p>	Session 215	<p>Parkinson's: Finally Crossing the Therapeutic Threshold</p> <p>NOVARTIS BALLROOM</p> <p>Parkinson's disease, the progressive, degenerative, neurological movement disorder that affects more than one million people in the United States, has no cure. Despite this, effective treatments are getting closer. Panel members describe the great progress being made with experimental therapies to prevent, slow, or halt disease progression.</p> <p>MODERATOR</p> <p>Michelle Cortez, Reporter, Bloomberg Businessweek</p> <p>Frank Bennett, PhD, Senior Vice President of Research, Isis Pharmaceuticals</p> <p>Michael Schwarzschild, MD, PhD, Chair, Parkinson Study Group (PSG) Executive Committee, MassGeneral Institute for Neurodegenerative Disease; Professor of Neurology, Harvard Medical School</p> <p>Clemens Scherzer, MD, Director, Neurogenomics Lab and Parkinson Personalized Medicine Program, Brigham and Women's Hospital/Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School</p> <p>Todd Sherer, PhD, CEO, The Michael J. Fox Foundation for Parkinson's Research</p>
		<p>4:40 PM</p>		<p>Session 216</p>
	Session 214	<p>Sleep and Consciousness: Clinical Need Versus Safety</p> <p>GE BALLROOM</p> <p>Sleep, which Shakespeare called "nature's soft nurse," is vital to mental and physical health. Compromised sleep is now an enormous burden, leading to daytime fatigue, sleepiness, and difficulty concentrating, interfering with a person's ability to maintain a daily routine. About 30 to 40 percent of adults report some symptoms of insomnia within a given year, with 10 to 15 percent noting chronic insomnia. Panel members review insomnia, its causes, how it impacts cognition and longevity, and technologies and programs to ensure optimal sleep.</p> <p>MODERATOR</p> <p>Martha Bebinger, Reporter, WBUR</p> <p>Matt Bianchi, MD, PhD, Chief, Division of Sleep Medicine, and Director, Sleep Laboratory, Massachusetts General Hospital Neurology; Assistant Professor of Neurology, Harvard Medical School</p> <p>Charles Czeisler, PhD, MD, Brigham and Women's Hospital Medicine and Neurology; Baldino Professor of Sleep Medicine, Harvard Medical School</p> <p>Patrick Purdon PhD, Associate Bioengineer, Massachusetts General Hospital - Department of Anesthesia, Critical Care, and Pain Medicine; Instructor of Anaesthesia, Harvard Medical School</p> <p>Darryle Schoepp, PhD, Vice President & Therapeutic Area Head, Neuroscience, Merck Research Laboratories</p>	<p>New Leaders at the Table: Filling the Gap Through Philanthropy?</p> <p>BIOGEN BALLROOM</p> <p>Hope for near-term change in CNS diseases lies not just with government and industry, but also with American philanthropy. In the face of fiscal stress on government budgets, family and disease foundations are committing substantial resources to help find cures for nearly all CNS diseases. Some of the most successful philanthropic entrepreneurs describe their approach, challenges and rewards. They also examine how peer-to-peer fundraising—and the Ice Bucket Challenge, in particular—has helped change the American donation landscape.</p> <p>MODERATOR</p> <p>David Shenk, Author, lecturer, filmmaker, Senior Advisor, Cure Alzheimer's Fund</p> <p>Meryl Comer, President, Geoffrey Beene Foundation Alzheimer's Initiative</p> <p>Henry McCance, Chairman Emeritus, Greylock Partners, Co-Founder, Cure Alzheimer's Fund</p> <p>Bill Sahlman, Dimitri V. D'Arbeloff - MBA Class of 1955 Professor of Business Administration, Senior Associate Dean for External Relations, Harvard Business School</p> <p>Steven Tregay, CEO, Forma Therapeutics</p> <p>Nancy and Pete Frates, The Pete Frates #3 Fund, Champions, ALS Ice Bucket Challenge</p> <p>Jeff Walker, Vice Chair, United Nations Envoy's Office for Health Finance and Malaria</p>	
		<p>5:50 PM</p>	<p>Adjourn</p>	
		<p>6:00 PM</p>	<p>Networking Dinner Reception</p> <p>TURNER'S RESTAURANT, WESTIN</p>	



7:30 AM	Continental Breakfast BIOGEN BALLROOM FOYER
8:00 AM	Reshaping Innovation Through Electronic Health BIOGEN BALLROOM
Session 301	Few organizations are as central to the electronically enabled delivery of care and related research than EPIC. CEO and Founder Judy Faulkner shares her unique perspective of having made a decades long journey from the earliest conception of an electronic medical record to today's near ubiquity in academic medicine. MODERATOR Gregg Meyer, MD, Chief Clinical Officer, Partners HealthCare Judy Faulkner, CEO and Founder, EPIC Systems
8:45 AM	Gene Editing, Gene Therapy, and the Eye as a Gateway BIOGEN BALLROOM
Session 302	Panel members detail why the future of CNS therapeutics is moving away from miracle drugs and gravitating towards personalized treatments using gene therapy. They also describe how the DNA-editing tool, CRISPR, is empowering scientists to make quick and inexpensive edits to a stretch of DNA with a level of ease and efficiency not previously possible. MODERATOR Jennifer Joe, MD, CEO, Medstro, Editor-In-Chief, MedTech Boston Katrine Bosley, CEO, Editas Medicine Eric Pierce, MD, PhD, Director, Retinal Degenerations Service, Massachusetts Eye and Ear; Solman and Libe Friedman Associate Professor of Ophthalmology, Harvard Medical School Philip Gregory, D. Phil, Senior Vice President, Research and CSO, Sangamo BioSciences David Meeker, MD, CEO, Genzyme
9:40 AM	MS Transformed: Harnessing Biology and Inflammation BIOGEN BALLROOM
Session 303	In MS, which affects at least 400,000 people in the U.S., the body's immune system attacks the myelin sheath protecting nerves in the brain, eyes, and spinal cord. While the exact cause of the condition is unclear, it is known to be triggered by an autoimmune response that causes inflammation in the central nervous system. Panel members describe latest research efforts, including development of therapies to stop MS attacks, vaccines using the body's immune system, and how gut microorganisms may influence immune system activity in people with MS. MODERATOR Mallika Marshall, MD, Medical Reporter, WBZ-TV Boston Tim Coetzee, PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society Al Sandrock, MD, PhD, Group Senior Vice President, Chief Medical Officer, Biogen Howard Weiner, MD, Founder and Director, Partners Multiple Sclerosis Center; Robert L. Kroc Professor of Neurology, Harvard Medical School Michael Panzara, MD, Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology, Genzyme
10:35 AM	Morning Break BIOGEN BALLROOM FOYER

11:00 AM	The Disruptive Dozen: 12 Technologies That Will Reinvent Neurocare BIOGEN BALLROOM
Session 304	Leading CNS faculty from the Brigham and Women's Hospital, Massachusetts General Hospital, and McLean Hospital nominated the technologies they believe will have the greatest impact on neurological care in the next decade. A panel of senior Partners neuroscience leaders chose the final list and ranking of these 12 disruptive technologies. This intriguing and fun session will let you in on how the experts view the future in their field. MODERATORS Rudolph Tanzi, PhD, Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School David Silbersweig, MD, Chairman, Brigham and Women's Hospital Psychiatry; Stanley Cobb Professor of Psychiatry, Harvard Medical School
12:00 PM	Lunch Program NOVARTIS BALLROOM
12:30 PM	The Century of the Molecule Becomes The Century of the System NOVARTIS BALLROOM
Session 305	One of the most influential voices in all of health care will share his reflections on how the world of medicine has changed and where we are headed. INTRODUCTION BY Marshall Moriarty, Retired Chair, Brigham and Women's Hospital, Board of Trustees Atul Gawande, MD, Executive Director, Ariadne Labs; General and Endocrine Surgery, BWH; Professor of Surgery, Harvard Medical School
1:15 PM	The Builder's Roundtable: Perspectives of Public/Private Payer Architects NOVARTIS BALLROOM
Session 306	Aetna CEO Mark Bertolini has been an influential voice in transforming healthcare payment and delivery systems. Peter Orszag, vice chairman of Citigroup and former Obama Administration budget director, was a key architect of the Affordable Care Act and one of the true go-to health care experts. Moderated by Tim Ferris, MD, one of the nation's leading population health experts, these two builders will discuss finance, technology and the future of innovation. MODERATOR Tim Ferris, MD, Senior Vice President, Population Health Management, Partners HealthCare Mark Bertolini, Chairman and CEO, Aetna Peter Orszag, Vice Chairman, Corporate and Investment Banking, Citigroup
2:15 PM	Closing Remarks and Preview of 2016 World Forum NOVARTIS BALLROOM
2:30 PM	Adjourn



About Partners Innovation

Innovation is the Strategic Connection to Partners Research Excellence

Partners HealthCare hospitals account for nearly \$1.5 billion in laboratory and clinical research annually. The magnitude and breadth of its research and clinical capabilities makes Partners HealthCare a compelling source for new insights in disease mechanisms, technology breakthroughs and patient care. Its hospitals have had enormous historic success transferring technology to companies that have led to substantial market outcomes.

Innovation, Partners HealthCare's 85-person business development and investment arm, is charged with enhancing those outcomes and the pathways that enable them. It is designed to be the catalyst that strategically connects the enormous strength of the research community at Partners to external collaborators. In doing so, the Innovation team aims to deliver a broader and more consistent flow of new products and services to enhance patient benefits. Its new "Market Sector" model was established to significantly increase opportunities for collaborative innovation.

Nine Market Sectors act as clinical "verticals" in core specialties: the neurosciences, cardiovascular care, cancer/pathology, anesthesia, radiology, surgery, orthopedics, medicine and pediatrics, and dermatology. Highly experienced industry executives were recruited to lead the Market Sectors. Their expertise includes senior key roles at companies such as Baxter, Bristol Meyers Squibb, Monsanto, Boston Scientific and PureTech. Each Sector is built around discrete strategies, goals, and metrics -- all drawing on deep domain knowledge. The Market Sector Leaders are charged with developing a "thesis for commercial investment" in Partners HealthCare research and clinical capabilities. To achieve successful engagements, Market Sectors focus on the attributes that industry seeks from academic medical centers, including disease insights, therapeutic options, technology, clinical expertise, compatibility with the company's portfolio and strategic direction, and a viable matching timeline for development.

Partners HealthCare offers a number of complementary strengths to industry collaborators including broad, scientific and clinical expertise; patient access; rapid point-of-care progression; and longitudinal, phenotyped patient data to inform studies of intervention, cost, outcomes, patient behavior and population health management. Partners also has substantial expertise in pre-clinical, clinical, post-approval and observational research. Its paradigm-shifting initiatives such as the Biobank, Big Data Platform, Connected Health, and Computational Pathology, as well as its other repositories offer industry an opportunity to drive the delivery of value based care. Finally, Partners hospitals offer unique insights as an accountable care organization and major purchaser and user of thousands of medical products daily.

The Market Sectors are designed to better align Partners HealthCare's ability to meet industry needs. Market Sector leadership engages at the decision-making level of key companies relevant to each sector. The Sectors deliver cohesive, tailored offerings to industry and also engage hospital leadership while efficiently conveying industry perspectives to Partners faculty and innovators to foster a lively, entrepreneurial culture. Team members in each Sector are mentored to enhance understanding of the related IP portfolio strengths and gaps, effectively engage in industry collaborations and experience the notion of "de-risking" product development through the industry lens. The Market Sectors analyze and share information on pattern of spend, state of pipeline, recent partnering decisions, IP portfolio and, importantly, desire to be a true partner.

Partners Innovation also seeks to bring more investment capital to support the commercialization of faculty and employee discoveries. The impact of its highly successful "Partners Innovation Fund" is rapidly increasing. More than \$200 million in new capital is being pursued through multiple new funds linked in novel ways to the technology strengths of the Partners family. If investment campaigns are successful, the funds will likely comprise the largest pool of capital directly tied to the technology of any academic center in the U.S. -- no surprise, considering the size and quality of the Partners HealthCare research enterprise.


Another substantial priority is further organizing the commercial application of a large portfolio of information technology (IT) solutions that Partners has developed and implemented for its own use. Spearheaded by the Innovation Business Development/Healthcare IT team, these technologies are being packaged into high-impact industry offerings. In parallel, leading health IT centers throughout Partners and its hospitals play a core role in the offerings provided to industry. This helps leverage the unique environment and broad resources available through Partners' health delivery system. Domain expertise and clinical context for industry solutions are provided in situations where understanding clinical, research, and administrative workflows are critical to the product development process.

Innovation is also responsible for myriad functions that enable groundbreaking research and translation. This includes the transaction of more than 1500 material transfers and nearly 200 industry-sponsored research agreements each year. Innovation handles an enormous patent portfolio with upwards of 300 US filings per year and total patent management several times that amount. With more than 2,400 agreements in place, Innovation also helps ensure full compliance with thousands of discrete financial requirements. Recent focused process improvements and tools have enhanced reliability, increased speed and reduced inventory -- in one case resulting in a greater than 85% enhancement.

As a matter of operating philosophy, Innovation seeks to run its operations like a business, organizing for outcomes and increased capabilities. The overriding goal is to ensure that Partners is the optimal collaborator with context of real-world success always in the forefront. This translates to organization-wide performance measures and better management of workflows, expectations, processes and approvals. The Innovation Advisory Board provides invaluable real-time, independent commercial guidance and contacts. The Board is complemented by the Commercialization Council consisting of top investigators from across Partners -- committed to ensuring that the capabilities, insights and needs of the research community are priorities in all Innovation activities and plans.

Innovation's entire approach is based on executing a discrete and measurable strategy in each of its operating units with an overriding sense of urgency, mirroring the stakes for patients and providers during this time of rapid transformation. ●

A rare commitment



We're steadfast in our commitment to the MS community, with experts dedicated to finding new approaches for confronting this disease.

Proud to support the World Medical Innovation Forum.

Learn more at
www.genzyme.com

genzyme
A SANOFI COMPANY

+ 0 → healthxl

**The global
clearing
house for
innovation in
healthcare**

healthxl.org

Sponsors

Thank You.

The 2015 World Medical Innovation Forum was made possible through the generosity of the following sponsors.

PRESENTING SPONSOR



Biogen

Cambridge, Massachusetts

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is the world's oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit our website.

www.biogen.com

STAKEHOLDER



Novartis

Basel, Switzerland

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of \$57.9 billion, while R&D throughout the Group amounted to approximately \$9.9 billion (\$9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit our website.

www.novartis.com

SPONSORS

STRATEGIC PARTNERS



Boston Scientific
Advancing science for life™

Boston Scientific
Boston, Massachusetts

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit our company's website.

www.bostonscientific.com



General Electric
Fairfield, Connecticut

MacDOUGALL
biomedical communications

MacDougall Biomedical Communications (MBI)
Boston, San Francisco, Munich

GE works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works. For more information, visit the company's website.

www.ge.com

MacDougall Biomedical Communications (MBI) is a team of experienced, multi-talented consultants spanning three locations – Boston, San Francisco and Munich – providing an integrated suite of media relations, investor relations, corporate communications and creative design services to life sciences companies of all sizes and stages, public and private. MBI offers its clients an unparalleled global network of contacts and expertise addressing all key audiences: investors, media, partners, and the medical and scientific communities at large. For more information, visit our company's website.

www.macbiocom.com

COLLABORATORS





AFFILIATE PARTNERS









MEDIA PARTNERS



The Massachusetts Life Sciences Center offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences.

masslifesciences.com



THE SCIENCE *of* POSSIBILITY

Vertex creates new possibilities in medicine to cure diseases and improve people's lives.

We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.



www.vrtx.com

©2015 Vertex Pharmaceuticals Incorporated

Information and Events



REGISTRATION HOURS

Monday, April 27 – 8:00am – 6:00pm
Tuesday, April 28 – 6:30am – 6:00pm
Wednesday, April 29 – 7:00am – 12:00pm

NAME BADGES

Name badges will be provided at Registration. On-site registration is available on the 4th floor outside the Biogen Ballroom. Name badges must be worn during all events including meals and receptions. Please return your badge to the Registration Desk when you depart. Badges will be recycled.

IMPORTANT LOCATIONS

Forum Luncheons and Dinner
Novartis Ballroom, 3rd Floor

Continental Breakfast – Daily
Biogen Ballroom Foyer, 4th Floor

Monday Evening Welcome Reception
Novartis Ballroom and GE Ballroom Foyers, 3rd Floor

Registration Desk and Information
Biogen Ballroom Foyer, 4th Floor

Tuesday Evening Networking Reception
Turner's Restaurant, at the Westin Copley Place

Registration on 4th Floor

WIRELESS ACCESS

Complimentary Internet access is available to all Forum attendees. To connect to the Internet:

STEP 1: Access your computer's Wireless Network connection

STEP 2: Click/connect to the network "Westin_Meeting Room" from the list of available networks

STEP 3: Open your Internet browser

STEP 4: The login page will ask for Password, first and last name, and you will have to accept the Westin's terms and conditions.

Password is: WMIF15

If you have an iPhone or iPad you must set your browser to "allow cookies" or "Block Cookies NEVER".

AUDIENCE RESPONSE SYSTEM

During this year's Forum we will utilize YORN. Throughout the meeting you will be asked to participate interactively via our audience response system. A link to the system is available via your mobile device at: worldmedicalinnovation.org

SPECIAL EVENTS

All World Medical Innovation Forum attendees are invited to attend a special Welcome Reception before Monday night's dinner and Tuesday night's off-site Networking Reception.

Monday Evening Welcome Reception
Network with Forum attendees during our Welcome Reception and Dinner at the Novartis Ballroom and GE Ballroom Foyers, 3rd Floor

Tuesday Networking Dinner Reception
The Tuesday Networking Dinner Reception will be held at Turner's Restaurant, at the Westin Copley Place. Please join us for this unique networking opportunity. Turner's Restaurant is located on the 2nd floor lobby level of the Westin Copley Place, found directly to the right of the Starbucks.

SPEAKER BIOS

A complete list of speakers and bios are available on line via the agenda on your web and mobile device at: worldmedicalinnovation.org/speakers

Connections



ONE-ON-ONE PARTNERING

One-on-One PARTNERING

a World Medical
Innovation Forum Event

We are pleased to announce One-on-One Partnering at this year's World Forum. MeetMax, a leader in managing private scheduled meetings within overall events, is providing scheduling solutions for registrants. Their meeting planner software allows guests to log into the site, search a database of attendees and request meetings with other attendees. For additional information, users should check their inboxes for login information, or inquire at the registration desk.

PARTNERING WITH PARTNERS HEALTHCARE

To schedule a meeting with Partners HealthCare Innovation staff during or after the Forum, please utilize the One-on-One Partnering system or stop by our exhibit space located on the fourth floor.

VISIT PARTNERS INNOVATION

We invite you to visit with Innovation staff at our dedicated space on the 4th Floor. Stop by to meet staff, get contact information and learn more about collaborative innovation at Partners HealthCare.

Connect with Us

 **LINKEDIN**
Partners HealthCare Innovation

 **TWITTER**
@PartnersWMIF

 **WEB**
worldmedicalinnovation.org



Acknowledgements



A HUMBLE THANK YOU

A special thanks to all of the speakers who gave so graciously of their time to be with us; to our Steering Committee who provided invaluable insight and resource to help plan this inaugural World Medical Innovation Forum; and to our Planning Committee staff for their unstinting commitment over the last 18 months to launch the World Medical Innovation Forum.

Planning Committee

- | | |
|--------------------|---------------------|
| Jonathan Behr, PhD | Jerry Mizer |
| Jamie Belkin | Beth Mollineaux |
| Greg Brace | Greg Mueller |
| Eric Castle | Judi Mullen |
| Rich Copp | Lynnea Oliverez |
| Gerald Couzens | Brandon Sarmas |
| Meaghan Doherty | Lisa Savin |
| Lynn Drake, MD | Diana Schwartzstein |
| Lorraine Fanton | Rudy Tanzi, PhD |
| Michael Freeman | Kari Watson |

Thank you for attending the 2015 World Medical Innovation Forum. We look forward to seeing you in 2016.

Clinical Focus: **Oncology**

Register Today at: worldmedicalinnovation.org





Cancer innovation on a global scale.

The 2016 World Medical Innovation Forum will highlight state-of-the-art and emerging approaches to diagnosing, treating and managing cancer—including early cancer detection and prevention; precision medicine and evolving models of care; immunological therapies; combination therapies to circumvent resistance; methods to find and develop new targets and new drugs as well as new informatics-driven tools and research approaches.

Join Us Next Year.

Special discounted pricing is available for registrants who sign up during this year's Forum (April 27-29, 2015). Visit the website or registration desk to take advantage of this special program.

www.worldmedicalinnovation.org

CANCER | ONCOLOGY
APRIL 25–27, 2016

WORLD MEDICAL
INNOVATION
F O R U M™



The Real-time Rx to improve Patient Experience.




Yorn® is a real-time data and analytics platform that enables organizations to improve patient experience, operational performance, and financial results. No one delivers higher patient and staff engagement throughout the care continuum than Yorn.




To learn more about your prescription for improved patient experience, visit yorn.com or email info@yorn.com today.

Maps

4TH FLOOR



3RD FLOOR





101 Huntington Avenue, 4th Floor | Boston, MA 02199
617-954-9500 | innovation.partners.org

